Dermatology News

Skin disease is more active than muscle disease in juvenile dermatomyositis and should be treated early and aggressively to limit its severity, according to a study.

Risankizumab is linked to significantly greater improvements in psoriatic arthritis signs and symptoms than placebo in patients with an inadequate response, or intolerance, to other drugs, according to a speaker at the EULAR 2021 Congress.

Upadacitinib maintains its efficacy over 56 weeks in patients with psoriatic arthritis who had a prior inadequate response to at least one biologic disease-modifying antirheumatic drug, according to data presented at the EULAR 2021 Virtual Congress.

As COVID-19 prevented millions of patients from seeing their doctors, the demand for telemedicine in dermatology increased.

Air pollution is a predictor of poor response to biological treatment in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, according to a poster session at the EULAR 2021 Congress.

Secukinumab yielded a significantly longer time to flare than placebo in pediatric patients with enthesitis-related arthritis and juvenile psoriatic arthritis, according to findings presented at the EULAR 2021 Congress.

Guselkumab 100 mg administered every 8 weeks results in “significantly higher” ACR20 response rates vs. placebo in patients with psoriatic arthritis who had an inadequate response to TNF inhibitors, according to data presented at the EULAR 2021 Virtual Congress.

In this video, April Armstrong, MD, MPH, of the Keck School of Medicine at the University of Southern California, Los Angeles, discussed improvements seen in secondary efficacy endpoints with topical tapinarof, an aryl hydrocarbon receptor modulating agent that is in late phase development, that were presented at AAD VMX 2021.

In this video, April Armstrong, MD, MPH, of the Keck School of Medicine at the University of Southern California, Los Angeles, spoke with Healio about findings from a study presented at AAD VMX 2021 that evaluated the use of topical roflumilast in patients with psoriasis.

Switching to bimekizumab resulted in better outcomes among certain patients with psoriasis who did not respond as well to adalimumab, according to results presented at AAD VMX 2021.